Clinical trial results:
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Summary

EudraCT number	2013-002780-26
Trial protocol	Outside EU/EEA
Global end of trial date	

Results information

Result version number	v1
This version publication date	13 June 2021
First version publication date	13 June 2021

Trial information

Trial identification

Sponsor protocol code	GS-US-292-0106

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01854775
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-001460-PIP01-13
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	06 October 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 May 2020
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of Cohort 1 were to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and TAF and confirm the dose of E/C/F/TAF STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF single-tablet regimen (STR) through Week 24 (Part B) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents. The primary objectives of Cohort 2 were to evaluate the PK of EVG and TAF in virologically suppressed HIV-1 infected children 6 to < 12 years of age weighing ≥ 25 kg administered E/C/F/TAF STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 in virologically suppressed HIV-1 infected children 6 to < 12 years of age weighing ≥ 25 kg (Part B). The primary objectives of Cohort 3 were to evaluate the PK of EVG and TAF and confirm the dose of STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose STR in virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 < 25 kg.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 May 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Thailand: 20
Country: Number of subjects enrolled	South Africa: 16
Country: Number of subjects enrolled	Uganda: 65
Country: Number of subjects enrolled	United States: 26
Country: Number of subjects enrolled	Zimbabwe: 2
Worldwide total number of subjects	129
EEA total number of subjects	0

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	79
Adolescents (12-17 years)	50
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants were enrolled at study sites in South Africa, Thailand, Uganda, United States of America, and Zimbabwe. The first participant was screened on 06 May 2013. The data are reported up to the data-cut date of 06 Oct 2020 for Week 48.

Period 1

Period 1 title	Treatment Phase (48 Weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

Arm description:

Human immunodeficiency virus (HIV)-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental
Investigational medicinal product name	E/C/F/TAF
Investigational medicinal product code	
Other name	Genvoya®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Arm title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

Arm description:

Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental
Investigational medicinal product name	E/C/F/TAF
Investigational medicinal product code	
Other name	Genvoya®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Arm title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg

Arm description:

Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental
Investigational medicinal product name	E/C/F/TAF (Low Dose)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Number of subjects in period 1	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Started	50	52	27
Completed	48	51	18
Not completed	2	1	9
Consent withdrawn by subject	1	1	-
Lost to follow-up	1	-	-
Still on Study up to the Data-Cut-Date	-	-	9

Period 2

Period 2 title	Extension Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

Arm description:

Human immunodeficiency virus (HIV)-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental

Investigational medicinal product name	E/C/F/TAF
Investigational medicinal product code	
Other name	Genvoya®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Arm title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

Arm description:

Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental
Investigational medicinal product name	E/C/F/TAF
Investigational medicinal product code	
Other name	Genvoya®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Arm title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg

Arm description:

Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Arm type	Experimental
Investigational medicinal product name	E/C/F/TAF (Low Dose)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablets administered once daily.

Number of subjects in period 2[1]	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Started	48	50	18
Completed	9	3	0
Not completed	39	47	18
Non- Compliance with Study Drug	1	-	-
Investigator's Discretion	1	-	-

Pregnancy	3	-	-
Still on Study	32	47	18
Lost to follow-up	2	-	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: 1 participant in arm 'Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg' completed the Treatment Phase, but did not enter in the Extension Phase.

Baseline characteristics

Reporting groups	
Reporting group title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg
Reporting group description:	
Human immunodeficiency virus (HIV)-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.	
Reporting group title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg
Reporting group description:	
Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.	
Reporting group title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Reporting group description:	
Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.	

Reporting group values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Number of subjects	50	52	27
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	15	10	6
standard deviation	± 1.9	± 1.2	± 1.9
Gender categorical			
Units: Subjects			
Female	28	30	17
Male	22	22	10
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	50	52	27
Race			
Units: Subjects			
Asian	6	13	3
Black or African American	44	37	24

White	0	2	0

Reporting group values	Total		
Number of subjects	129		
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	- -		
Gender categorical Units: Subjects			
Female	75		
Male	54		
Ethnicity Units: Subjects			
Not Hispanic or Latino	129		
Race Units: Subjects			
Asian	22		
Black or African American	105		
White	2		

End points

End points reporting groups

Reporting group title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

Reporting group description:

Human immunodeficiency virus (HIV)-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

Reporting group description:

Human immunodeficiency virus (HIV)-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Primary: Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)

End point title	Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)[1][2]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). The PK Substudy Analysis Set included all enrolled and treated participants from Part A who had any nonmissing key PK parameters (AUCtau, AUClast, Cmax) from Week 4 intensive PK data for the respective analyte.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: hr*ng/mL				
arithmetic mean (standard deviation)	23840.1 (± 6076.15)			

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUCtau of EVG (Cohort 2)

End point title	PK Parameter: AUCtau of EVG (Cohort 2)[3][4]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: hr*ng/mL				
arithmetic mean (standard deviation)	33813.9 (± 19536.30)			

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUCtau of EVG (Cohort 3)

End point title	PK Parameter: AUCtau of EVG (Cohort 3)[5][6]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). The Intensive PK Analysis Set included all enrolled and treated participants who had any nonmissing key PK parameters (AUCtau, AUClast, Cmax) from Week 2 intensive PK data for the respective analyte.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: hr*ng/mL				
arithmetic mean (standard deviation)	29666.6 (± 17321.81)			

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)

End point title	PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)[7][8]

End point description:

AUClast is defined as the concentration of drug from time zero to the last observable concentration. Participants in the PK Substudy Analysis Set were analyzed.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: hr*ng/mL				
arithmetic mean (standard deviation)	188.9 (± 105.45)			

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUClast of TAF (Cohort 2)

End point title	PK Parameter: AUClast of TAF (Cohort 2)[9][10]

End point description:

AUClast is defined as the concentration of drug from time zero to the last observable concentration. Participants in the PK Substudy Analysis set were analyzed.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: hr*ng/mL				

arithmetic mean (standard deviation)	332.9 (± 149.12)			

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUCtau of TAF (Cohort 3)

End point title	PK Parameter: AUCtau of TAF (Cohort 3)[11][12]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Participants in the Intensive PK Analysis Set (all enrolled and treated participants who had any nonmissing key PK parameters [AUCtau, AUClast, Cmax] from Week 2 intensive PK data for the respective analyte) with available data were analyzed.

End point type	Primary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: hr*ng/mL				
arithmetic mean (standard deviation)	366.4 (± 144.91)			

Statistical analyses

No statistical analyses for this end point

Primary: Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)

End point title	Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)[13][14]

End point description:

Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:

• Fatal
• Life-threatening
• Disabling/incapacitating
• Results in hospitalization or prolongs a hospital stay
• A congenital abnormality
• Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above. Participants in the Safety Analysis Set (all participants who received at least 1 dose of study drug) with available data were analyzed.

End point type	Primary

End point timeframe:

From first dose date up to Week 24

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)				
Any TEAEs	81.3			
SAEs	8.3			

Statistical analyses

No statistical analyses for this end point

Primary: Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

End point title	Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs[15][16]

End point description:

TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:
• Fatal
• Life-threatening
• Disabling/incapacitating
• Results in hospitalization or prolongs a hospital stay
• A congenital abnormality
• Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above. Participants in the Safety Analysis Set with available data were analyzed.

End point type	Primary

End point timeframe:

From first dose date up to Week 24

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: percentage of participants				
number (not applicable)				
Any TEAEs	73.9			
SAEs	0			

Statistical analyses

No statistical analyses for this end point

Primary: Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs

End point title	Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs[17][18]

End point description:

TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:
• Fatal
• Life-threatening
• Disabling/incapacitating
• Results in hospitalization or prolongs a hospital stay
• A congenital abnormality
• Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above. Participants in the Safety Analysis Set were analyzed.

End point type	Primary

End point timeframe:

From first dose date up to Week 24

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical comparison was planned or performed.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)				
Any TEAEs	70.4			
SAEs	3.7			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 1)

End point title	PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 1)[19]

End point description:

Ctau is defined as the observed drug concentration at the end of the dosing interval. Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG (n = 24)	300.8 (± 243.69)			
FTC (n = 23)	102.4 (± 39.85)			
TFV (n = 24)	10.0 (± 2.13)			
COBI (n = 15)	25.0 (± 44.97)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 2)

End point title	PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 2)[20]

End point description:

Ctau is defined as the observed drug concentration at the end of the dosing interval. Participants in the PK Substudy Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

(pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG	370.0 (± 438.52)			
FTC	114.9 (± 27.70)			
TFV	15.1 (± 3.77)			
COBI	96.0 (± 162.01)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)

End point title	PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)[21]

End point description:

Ctau is defined as the observed drug concentration at the end of the dosing interval. Participants in the Intensive PK Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG (n = 22)	277.5 (± 223.43)			
FTC (n = 27)	82.5 (± 26.47)			
TFV (n = 27)	11.4 (± 2.65)			
COBI (n = 18)	23.0 (± 23.02)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)

End point title	PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)[22]

End point description:

Cmax is defined as the maximum concentration of drug. Participants in the PK Substudy Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG	2229.6 (± 427.93)			
TAF	166.8 (± 107.44)			
FTC	2265.0 (± 510.55)			
TFV	17.6 (± 4.18)			
COBI	1202.4 (± 421.21)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)

End point title	PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)[23]

End point description:

Cmax is defined as the maximum concentration of drug. Participants in the PK Substudy Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG	3055.2 (± 1180.90)			
TAF	313.3 (± 191.68)			
FTC	3397.4 (± 916.06)			
TFV	26.1 (± 5.43)			
COBI	2079.4 (± 970.81)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)

End point title	PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)[24]

End point description:

Cmax is defined as the maximum concentration of drug. Participants in the Intensive PK Analysis Set

were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: ng/mL				
arithmetic mean (standard deviation)				
EVG	3297.2 (± 1720.38)			
TAF	286.6 (± 206.97)			
FTC	3007.4 (± 1138.10)			
TFV	19.6 (± 4.72)			
COBI	1525.5 (± 788.12)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: CL of EVG and TAF (Cohort 1)

End point title	PK Parameter: CL of EVG and TAF (Cohort 1)[25]

End point description:

Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. Participants in the PK Substudy Analysis Set with available data were analyzed

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: L/hr				
arithmetic mean (standard deviation)				
EVF (n = 24)	6.7 (± 1.74)			
TAF (n = 23)	68.6 (± 52.64)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: CL of EVG and TAF (Cohort 2)

End point title	PK Parameter: CL of EVG and TAF (Cohort 2)[26]

End point description:

Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: L/hr				
arithmetic mean (standard deviation)				
EVG (n = 22)	6.3 (± 5.11)			
TAF (n = 11)	31.9 (± 11.21)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: CL of EVG and TAF (Cohort 3)

End point title	PK Parameter: CL of EVG and TAF (Cohort 3)[27]

End point description:

Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. Participants in the Intensive PK Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: L/hr				
arithmetic mean (standard deviation)				
EVG (n = 24)	3.4 (± 1.79)			
TAF (n = 17)	18.5 (± 6.27)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Vz of EVG and TAF (Cohort 1)

End point title	PK Parameter: Vz of EVG and TAF (Cohort 1)[28]

End point description:

Vz is defined as the volume of distribution of the drug after intravenous administration. Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: liters				
arithmetic mean (standard deviation)				
EVG (n = 24)	60.5 (± 18.77)			
TAF (n = 23)	49.7 (± 32.54)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Vz of EVG and TAF (Cohort 2)

End point title	PK Parameter: Vz of EVG and TAF (Cohort 2)[29]

End point description:

Vz is defined as the volume of distribution of the drug after intravenous administration. Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: liters				
arithmetic mean (standard deviation)				
EVG (n = 14)	46.8 (± 36.02)			
TAF (n = 11)	28.6 (± 25.74)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: Vz of EVG and TAF (Cohort 3)

End point title	PK Parameter: Vz of EVG and TAF (Cohort 3)[30]

End point description:

Vz is defined as the volume of distribution of the drug after intravenous administration. Participants in the Intensive PK Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: liters				
arithmetic mean (standard deviation)				
EVG (n = 14) TAF (n = 17)	28.5 (± 28.30) 16.3 (± 11.07)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)

End point title	PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)[31]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
FTC (n = 24) TFV (n = 23) COBI (n = 23)	14424.4 (± 3452.88) 287.6 (± 54.09) 8240.8 (± 2972.94)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)

End point title	PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)[32]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Participants in the PK Substudy Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
FTC (n = 22)	20629.2 (± 3906.01)			
TFV (n = 23)	440.2 (± 92.13)			
COBI (n = 20)	15890.7 (± 8208.78)			

Statistical analyses

No statistical analyses for this end point

Secondary: PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)

End point title	PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)[33]

End point description:

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Participants in the Intensive PK Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
FTC (n = 27)	19468.1 (± 5635.74)			
TFV (n = 27)	334.9 (± 76.77)			
COBI (n = 21)	14485.2 (± 7166.10)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis[34]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Full analysis set included all participants who were enrolled in the study and had received at least 1 dose of study drug.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	90.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis[35]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	92.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis[36]

End point description:

The percentage of participants with HIV-1 RNA < 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	94.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis[37]

End point description:

The percentage of participants with HIV-1 RNA < 400 Copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	94.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis[38]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis[39]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	98.1			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis[40]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis[41]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses[42]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	90.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses[43]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	92.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses[44]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				

number (not applicable)	94.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses[45]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of participants				
number (not applicable)	94.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses[46]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses[47]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses[48]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses[49]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses[50]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses[51]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses[52]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	93.8			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses[53]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	95.8			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses[54]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	97.9			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

End point title	Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses[55]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	97.9			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses[56]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses[57]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses[58]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses

End point title	Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses[59]

End point description:

The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of participants				
number (not applicable)	100			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses[60]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 24

Notes:

[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses

End point title	Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses[61]

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Week 48

Notes:

[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of participants				
number (not applicable)	96.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24

End point title	Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24[62]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: copies/mL				
arithmetic mean (standard deviation)				
Baseline (n = 50) Change at Week 24 (n = 48)	4.62 (± 0.587) -3.25 (± 0.645)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48

End point title	Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48[63]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: copies/mL				
arithmetic mean (standard deviation)				
Baseline (n = 50)	4.62 (± 0.587)			
Change at Week 48 (n = 48)	-3.26 (± 0.712)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in CD4+ Cell Count at Week 24

End point title	Cohort 1: Change From Baseline in CD4+ Cell Count at Week 24[64]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline (n = 50)	471 (± 212.2)			
Change at Week 24 (n = 48)	191 (± 175.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48

End point title	Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48[65]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline (n = 50)	471 (± 212.2)			
Change at Week 48 (n = 48)	224 (± 170.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24

End point title	Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24[66]

End point description:

Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline	961 (± 275.5)			
Change at Week 24	-118 (± 194.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48

End point title	Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48[67]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline (n = 52)	961 (± 275.5)			
Change at Week 48 (n = 50)	-66 (± 203.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24

End point title	Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24[68]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline (n = 27)	1153 (± 459.9)			
Change at Week 24 (n = 17)	-137 (± 278.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48

End point title	Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48[69]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: cells/µL				
arithmetic mean (standard deviation)				
Baseline (n =27)	1153 (± 459.9)			
Change at Week 48 (n = 24)	-179 (± 319.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24

End point title	Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24[70]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline (n = 50)	23.6 (± 8.80)			
Change at Week 24 (n = 48)	7.7 (± 4.77)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48

End point title	Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48[71]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reporting statistics for Cohort 1 only.

End point values	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline (n = 50)	23.6 (± 8.80)			
Change at Week 48 (n = 47)	9.3 (± 5.19)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24

End point title	Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24[72]

End point description:

Participants in the Full Analysis Set were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline	38.2 (± 6.44)			
Change at Week 24	-0.8 (± 3.97)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48

End point title	Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48[73]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 2 only.

End point values	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	52			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline (n = 52)	38.2 (± 6.44)			
Change at Week 48 (n = 50)	-0.6 (± 4.37)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24

End point title	Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24[74]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 24

Notes:

[74] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline (n = 27)	35.9 (± 6.73)			
Change at Week 24 (n = 17)	0.0 (± 4.40)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48

End point title	Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48[75]

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary

End point timeframe:

Baseline, Week 48

Notes:

[75] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reporting statistics for Cohort 3 only.

End point values	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: percentage of CD4+ cell				
arithmetic mean (standard deviation)				
Baseline (n = 27)	35.9 (± 6.73)			
Change at Week 48 (n = 24)	0.2 (± 3.78)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

First dose date up to 89 months

Adverse event reporting additional description:

The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Adverse events were coded according to MedDRA Version 21.1 (for Cohorts 1 and 2) and MedDRA Version 23.0 (for Cohort 3).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.1

Reporting groups

Reporting group title	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg

Reporting group description:

HIV-infected, ARV treatment-naive adolescents (12 to < 18 years of age) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) received E/C/F/TAF (150/150/200/10 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who completed 48 weeks of study treatment had the option to receive E/C/F/TAF in an extension phase of the study until: a) the
participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Reporting group title	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg

Reporting group description:

Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) received E/C/ F/TAF (90/90/120/6 mg) FDC tablets, once daily orally with food for 48 weeks. Participants who attained a weight of ≥ 25 kg during the course of the study were switched to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who completed 48 weeks of study treatment had the option to continue E/C/F/TAF in an extension phase of the study until: a) the participant turned 18 years old and E/C/F/TAF was commercially available for adults in the country in which the participant was enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant was enrolled; or c) Gilead elected to terminate development of E/C/F/TAF in that country.

Serious adverse events	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 50 (16.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Injury, poisoning and procedural complications			
Radius fracture			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Epilepsy			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Autoimmune uveitis			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			

subjects affected / exposed	2 / 50 (4.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute psychosis			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Agitation			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar I disorder			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conduct disorder			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug abuse			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance abuse			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary retention			

subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 50 (0.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	1 / 50 (2.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg	Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg	Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 50 (94.00%)	38 / 52 (73.08%)	19 / 27 (70.37%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	4 / 50 (8.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences (all)	4	0	1
Anogenital warts			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	4	0	0
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	3 / 50 (6.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	4	1	0
Respiratory, thoracic and mediastinal			

disorders			
Cough			
subjects affected / exposed	8 / 50 (16.00%)	6 / 52 (11.54%)	5 / 27 (18.52%)
occurrences (all)	9	6	8
Rhinorrhoea			
subjects affected / exposed	3 / 50 (6.00%)	5 / 52 (9.62%)	0 / 27 (0.00%)
occurrences (all)	4	5	0
Rhinitis allergic			
subjects affected / exposed	0 / 50 (0.00%)	5 / 52 (9.62%)	1 / 27 (3.70%)
occurrences (all)	0	8	1
Oropharyngeal pain			
subjects affected / exposed	3 / 50 (6.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	3	2	0
Epistaxis			
subjects affected / exposed	0 / 50 (0.00%)	1 / 52 (1.92%)	2 / 27 (7.41%)
occurrences (all)	0	1	2
Product issues			
Product size issue			
subjects affected / exposed	5 / 50 (10.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	5	1	0
Investigations			
Weight decreased			
subjects affected / exposed	4 / 50 (8.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences (all)	4	0	1
Injury, poisoning and procedural complications			
Skin abrasion			
subjects affected / exposed	0 / 50 (0.00%)	3 / 52 (5.77%)	1 / 27 (3.70%)
occurrences (all)	0	3	1
Contusion			
subjects affected / exposed	0 / 50 (0.00%)	3 / 52 (5.77%)	0 / 27 (0.00%)
occurrences (all)	0	3	0
Tooth fracture			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Nervous system disorders			

Headache			
subjects affected / exposed	13 / 50 (26.00%)	6 / 52 (11.54%)	0 / 27 (0.00%)
occurrences (all)	16	6	0
Dizziness			
subjects affected / exposed	6 / 50 (12.00%)	2 / 52 (3.85%)	0 / 27 (0.00%)
occurrences (all)	6	2	0
Somnolence			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	5 / 50 (10.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	7	2	0
Lymphadenopathy			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	10 / 50 (20.00%)	13 / 52 (25.00%)	4 / 27 (14.81%)
occurrences (all)	12	13	4
Diarrhoea			
subjects affected / exposed	14 / 50 (28.00%)	7 / 52 (13.46%)	2 / 27 (7.41%)
occurrences (all)	21	7	2
Abdominal pain			
subjects affected / exposed	11 / 50 (22.00%)	9 / 52 (17.31%)	0 / 27 (0.00%)
occurrences (all)	12	9	0
Nausea			
subjects affected / exposed	15 / 50 (30.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	16	1	0
Dental caries			
subjects affected / exposed	6 / 50 (12.00%)	3 / 52 (5.77%)	0 / 27 (0.00%)
occurrences (all)	6	3	0
Abdominal pain upper			
subjects affected / exposed	5 / 50 (10.00%)	1 / 52 (1.92%)	1 / 27 (3.70%)
occurrences (all)	8	1	1
Constipation			

subjects affected / exposed	3 / 50 (6.00%)	2 / 52 (3.85%)	2 / 27 (7.41%)
occurrences (all)	5	2	2
Gastritis			
subjects affected / exposed	5 / 50 (10.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	5	1	0
Skin and subcutaneous tissue disorders			
Seborrhoeic dermatitis			
subjects affected / exposed	7 / 50 (14.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	8	0	0
Rash			
subjects affected / exposed	3 / 50 (6.00%)	1 / 52 (1.92%)	1 / 27 (3.70%)
occurrences (all)	3	1	1
Rash papular			
subjects affected / exposed	5 / 50 (10.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	7	0	0
Acne			
subjects affected / exposed	4 / 50 (8.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	4	0	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	3 / 50 (6.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	5	1	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	19 / 50 (38.00%)	14 / 52 (26.92%)	8 / 27 (29.63%)
occurrences (all)	38	19	8
Respiratory tract infection			
subjects affected / exposed	19 / 50 (38.00%)	9 / 52 (17.31%)	0 / 27 (0.00%)
occurrences (all)	44	12	0
Malaria			
subjects affected / exposed	9 / 50 (18.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	10	1	0
Urinary tract infection			
subjects affected / exposed	7 / 50 (14.00%)	2 / 52 (3.85%)	1 / 27 (3.70%)
occurrences (all)	13	2	1
Body tinea			

subjects affected / exposed	7 / 50 (14.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences (all)	7	0	1
Nasopharyngitis			
subjects affected / exposed	3 / 50 (6.00%)	2 / 52 (3.85%)	3 / 27 (11.11%)
occurrences (all)	3	2	4
Tonsillitis			
subjects affected / exposed	5 / 50 (10.00%)	1 / 52 (1.92%)	2 / 27 (7.41%)
occurrences (all)	5	1	2
Gastroenteritis			
subjects affected / exposed	4 / 50 (8.00%)	3 / 52 (5.77%)	0 / 27 (0.00%)
occurrences (all)	4	3	0
Pneumonia			
subjects affected / exposed	6 / 50 (12.00%)	1 / 52 (1.92%)	0 / 27 (0.00%)
occurrences (all)	8	1	0
Vulvovaginal candidiasis			
subjects affected / exposed	5 / 50 (10.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	9	0	0
Conjunctivitis			
subjects affected / exposed	4 / 50 (8.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	4	0	0
Pharyngitis			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences (all)	3	0	1
Rhinitis			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	1 / 27 (3.70%)
occurrences (all)	3	0	1
Folliculitis			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	4	0	0
Hordeolum			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	4	0	0
Nasal herpes			
subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Proctitis gonococcal			

subjects affected / exposed	3 / 50 (6.00%)	0 / 52 (0.00%)	0 / 27 (0.00%)
occurrences (all)	3	0	0
Metabolism and nutrition disorders			
Vitamin D deficiency			
subjects affected / exposed	8 / 50 (16.00%)	3 / 52 (5.77%)	0 / 27 (0.00%)
occurrences (all)	8	3	0
Decreased appetite			
subjects affected / exposed	2 / 50 (4.00%)	0 / 52 (0.00%)	4 / 27 (14.81%)
occurrences (all)	2	0	4

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 March 2013	- Corrected the measurement unit for the CD4 cell count inclusion criterion - Increased the minimum number of participants in each age subgroup of Part A - Added a 24-hour time point to the intensive PK sampling times - Updated the list of disallowed and discouraged medications in the study
09 January 2015	- Added palatability and acceptability assessment procedures - Added Cohort 2 Part A with virologically suppressed children 6 to < 12 years of age weighing ≥ 25 kg
11 August 2016	- Added Cohort 2 Part B with virologically suppressed children 6 to < 12 years of age weighing ≥ 25 kg
11 June 2018	Added Cohort 3, to comprise virologically suppressed, HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to < 25 kg, in which to allow evaluation of the PK, safety, efficacy, and tolerability of the E/C/F/TAF low dose tablet (E/C/F/TAF 90/90/120/6 mg).
17 August 2018	Updated CD4 cell inclusion criteria for Cohort 3, and added time points for palatability and acceptability assessments.
21 February 2020	Clarified that fasting was not required in advance of sample collection for evaluation of urine renal safety parameters and serum bone safety parameters.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/30169223

http://www.ncbi.nlm.nih.gov/pubmed/27765666